Christopher O’Donnell

Christopher O’Donnell

Company: Novartis AG

Job title: Vice President - Global Translational Medicine & Head of Cardiovascular & Metabolism


Panel Discussion: Spearheading the New Wave of Therapies & Approaches to Treating HFpEF 2:30 pm

Sharing latest data on the categories of medications that are on the threshold of being in the next phase-II and phase-III clinical trials Understanding the landscape of CCB, Baroreflex and other therapies in the production pipeline and the impacts these could have on HFpEF patientsRead more

day: Day Two

Integrating Biomarkers & Genomics to Decision-Making Protocol on HFpEF Treatments 11:10 am

Introducing one of the largest genome wide studies for heart failure published Leveraging the use of genomics and heart failure in decision making for both HFpEF and HFrEF in the area of cell and gene therapy Uncovering tissue targeting and tissue specificity of these emerging therapies for effective early treatment and preventionRead more

day: Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.